Novartis Said to Near at Least $70-Per-Share Deal for Avidity Bloomberg.com Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports CNBC Novartis is said to near acquisition of Avidity Biosciences for more than $70 a share (NVS:NYSE) Seeking Alpha Novartis set to announce $10bn plus Avidity Biosciences purchase Financial Times Novartis nears deal …
Read More »